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… the aim of oxygen therapy should be to increase the 
delivery of oxygen rather than to reach any arbitrary 
concentration in the arterial blood.
EJM Campbell [1]
Is administration of oxygen, the most widely prescribed 
drug in the formulary, free of risks to nonhypoxemic 
patients with regional ischemia? Hyperoxia marginally 
increases the arterial blood oxygen content (CaO2), 
theoretically increasing tissue oxygen delivery (DO2) 
assuming no reduction in tissue blood ﬂ  ow. However, 
oxygen causes constriction of the coronary, cerebral, 
renal and other key vasculatures – and if regional per-
fusion decreases concomitantly with blood hyperoxyge-
nation, one would have a seemingly paradoxical situation 
in which the administration of oxygen may place tissues 
at increased risk of hypoxic stress. Any tissue damage in 
the course of oxygen administration would plausibly be 
attributed to the underlying disease process. Ascribing 
hypoxic damage to oxygen administration is counter-
intuitive and is diﬃ     cult to accept without a receptive 
mindset. Considering the ubiquity of oxygen therapy, the 
continued low threshold for its administration, and the 
widespread belief that its use is justiﬁ  ed and safe [2,3], we 
believe it is important to revisit the arguments made to 
justify the status quo.
Owing to the vasoconstrictor eﬀ  ects on the coronary, 
cerebral, renal and other key vasculatures, there are many 
scenarios in which administration of oxygen decreases 
the perfusion to vital organs to a greater extent than the 
small increase in CaO2, thereby actually reducing DO2. 
Th   e calculated CaO2 increases with normobaric 
hyperoxia (assuming all hemoglobin is already saturated) 
by only 0.03 ml/l per mmHg. With increases in alveolar 
PaO2 from 100 to 600 mmHg, CaO2 increases by 15 ml/l, 
or about ~7.5% assuming a hemoglobin concentration of 
150 g/l.
In healthy adults, hyperoxia decreases cerebral blood 
ﬂ  ow by 11 to 33% [4,5]. Administration of high oxygen 
concentrations is therefore likely to decrease brain DO2. 
Despite this known eﬀ  ect of hyperoxia on cerebral blood 
ﬂ  ow, and the published recommendations [6], patients 
with stroke – even those with satisfactory arterial satura-
tions – are routinely administered oxygen [4]. Does this 
matter? Possibly. Although Singhal and colleagues repor-
ted transient improvement in patients with ische  mic 
strokes [7], survival at 7 months for patients with mild or 
moderate strokes is signiﬁ   cantly greater in those 
administered air than in those given 100% oxygen for the 
ﬁ  rst 24 hours after the event [8].
Hyperoxia-induced decreases in regional DO2 are not 
conﬁ   ned to the brain. Normobaric hyperoxia reduces 
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Supplementary oxygen is routinely administered to 
patients, even those with adequate oxygen saturations, 
in the belief that it increases oxygen delivery. But 
oxygen delivery depends not just on arterial oxygen 
content but also on perfusion. It is not widely 
recognized that hyperoxia causes vasoconstriction, 
either directly or through hyperoxia-induced 
hypocapnia. If perfusion decreases more than arterial 
oxygen content increases during hyperoxia, then 
regional oxygen delivery decreases. This mechanism, 
and not (just) that attributed to reactive oxygen 
species, is likely to contribute to the worse outcomes 
in patients given high-concentration oxygen in the 
treatment of myocardial infarction, in postcardiac 
arrest, in stroke, in neonatal resuscitation and in the 
critically ill. The mechanism may also contribute to 
the increased risk of mortality in acute exacerbations 
of chronic obstructive pulmonary disease, in which 
worsening respiratory failure plays a predominant 
role. To avoid these eff  ects, hyperoxia and hypocapnia 
should be avoided, with oxygen administered only to 
patients with evidence of hypoxemia and at a dose 
that relieves hypoxemia without causing hyperoxia.
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© 2011 BioMed Central Ltdcoronary blood ﬂ  ow by 8 to 29% in normal subjects and 
in patients with coronary artery disease or chronic heart 
failure [9]. Th  e reduction in coronary artery ﬂ  ow  is 
associated with a reduction in myocardial DO2 and oxy-
gen consumption [10]. Th  ese  eﬀ  ects may explain disturb-
ing ﬁ  ndings in patients with coronary artery disease. As 
early as 1950 Russek and colleagues reported that supple-
mental oxygen failed to reduce electrocardio  graphic 
signs of ischemia or reduce anginal pain in patients with 
myocardial infarction [11]. In 1969 Bourassa and 
colleagues proposed that hyperoxia-induced decreases in 
coronary blood ﬂ   ow provoke myocardial ischemia in 
patients with severe coronary artery disease [12]. Th  en  in 
1976, in a double-blind randomized controlled trial, 
Rawles and Kenmure reported greater serum aspartate 
aminotransferase levels, indicating increased infarct size, 
in patients with acute myocardial infarction receiving 
high-ﬂ  ow oxygen compared with room air [13]. Th  ey  also 
observed a nonsigniﬁ  cant tripling of the death rate in 
those patients.
Given these concerns, the Emergency Oxygen Guide-
line Group of the British Th   oracic Society called for ‘large 
randomised trials of oxygen therapy for non-hypoxaemic 
patients with acute cardiac and cerebral ischaemia’ [14]. 
Conti, in a recent editorial [15], reminded readers that 
that there is only level C evidence for the administration 
of supplemental oxygen to patients with uncomplicated 
ST elevation in myocardial infarction during the ﬁ  rst 
6 hours [16]. Based on currently available evidence, the 
UK National Institute for Health and Clinical Excellence 
guidelines have recently emphasized that ‘supplementary 
oxygen should not be routinely administered to patients 
with acute chest pain of suspected cardiac origin, but 
that oxygen saturation levels should be monitored and 
used to guide its administration’ [17]. Similar cautions 
have been expressed about the use of oxygen for the 
treatment of traumatic brain injury [18].
Th  e mechanisms by which hyperoxia causes systemic 
vasoconstriction remain uncertain. Recent work focuses 
on the inhibition of vasodilators (prostaglandins, nitric 
oxide) by reactive oxygen species generated as a result of 
the hyperoxia [19-23]. Other work suggests that reactive 
oxygen species activate brainstem respiratory neurons 
[24], but this suggestion needs to be established as occur-
ring under normobaric conditions. Th   e role of hyperoxia-
induced hypocapnia (that is, the reverse Haldane eﬀ  ect) 
remains contentious [3,25]. Regardless of the underlying 
mechanism(s), the importance of considering the eﬀ  ects 
of both PaO2 and PaCO2 on vascular tone is evident in a 
study in which both hyperoxia and hypocapnia 
independently increased cerebrovascular resistance and 
reduced cerebral blood ﬂ  ow [5]. Indeed, in some situa-
tions, the vasoconstrictive eﬀ  ects of hyperoxia may be 
predominantly due to the concomitant hypocapnia 
[25,26]. Positron emission tomography provides similar 
results: the reduction of cerebral blood ﬂ   ow and the 
increase in oxygen extraction during inhalation of 100% 
oxygen is completely reversed when subjects breathe 
carbogen (5% carbon dioxide, 95% oxygen) [27]. Th  ese 
observations emphasize the importance of independent 
control of arterial PCO2 and PO2 – possibly using 
dynamic forcing of alveolar gases (for example [28]) or 
sequential gas delivery (for example [29]) – when studying 
the independent eﬀ   ects of PO2 and PCO2 on regional 
perfusions. Th  ese observations also suggest that adding 
carbon dioxide to oxygen may oﬀ  set the vasoconstriction 
due to hyperoxia or hypoxia-induced hypocapnia.
Th   ere are other clinical situations in which the routine 
administration of high-concentration oxygen may lead to 
worse outcomes, although primarily through mecha  nisms 
other than changes in regional perfusion. Austin and 
colleagues recently reported in a randomized controlled 
trial that patients with acute exacerbations of chronic 
obstruc  tive pulmonary disease have a twofold to fourfold 
increased mortality when treated with high-ﬂ  ow oxygen 
compared with oxygen titrated to result in an arterial 
oxygen saturation between 88 and 92% [30]. Although 
several mechanisms may account for these ﬁ  ndings [31], 
worsening respiratory failure is probably the predomi-
nant mechanism. Of the patients whose arterial blood 
gases were measured within 30 minutes of presentation 
to hospital, those who received high-concentration 
oxygen were more likely to have hypercapnia (mean 
diﬀ  erence  PaCO2 34 mmHg) or respiratory acidosis 
(mean diﬀ  erence pH 0.12).
Adverse outcomes with hyperoxia have also been 
reported in critically ill patients admitted to the intensive 
care unit; a high PaO2 in the ﬁ  rst 24 hours after admission 
is independently associated with in-hospital mortality 
[32]. In this study a U-shaped curve of mortality with 
PaO2 was observed, illustrating the risks of both hypoxia 
and hyperoxia. Kilgannon and colleagues recently repor-
ted that patients administered high-concentration oxygen 
resulting in hyperoxia (PaO2 >300 mmHg) following 
cardiac arrest have increased in-hospital mortality, a 
ﬁ  nd  ing they attributed to increased oxidative stress asso-
ciated with hyperoxia [33]. However, because a subse-
quent study was unable to replicate these ﬁ  ndings [34], 
randomized controlled trials will be required to resolve 
the clinical uncertainty.
Neonatal resuscitation is the clinical situation in which 
administration of 100% oxygen has most clearly been 
demonstrated to increase the risk of death [35,36]. Th  is 
has resulted in a radical change in practice whereby room 
air rather than oxygen is now the recommended resus  ci-
tation regime [36].
Considering the ubiquity of the administration of 
supplemental oxygen, there are surprisingly few 
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role when hypoxemia is absent. Th   is may reﬂ  ect the fact 
that its usage is so embedded in clinical practice that it is 
accepted as safe [2]. Nevertheless, there are some 
situations in which supplemental oxygen administration 
is useful: treatment of cluster headache [37], reducing the 
oxidative stress associated with colon surgery [38], and 
the prevention of desaturation during endoscopy [39,40]. 
Supplemental oxygen adminis  tration can, however, have 
the unintended side eﬀ   ect of delaying recognition by 
oximetry of hypo  venti  lation [41,42]. Until recently many 
studies had indicated that supple  mentary oxygen reduced 
postoperative nausea and vomit  ing, but the current 
status is ambiguous (for example [43-46]). Similarly, 
oxygen was thought to reduce postsurgical infections – 
but more recent studies (see [47] for a partial summary) 
have cast doubt on the original ﬁ  ndings.  More  over, 
ventilation with high inspired oxygen concen  trations 
during surgery leads to subsequent impairment of 
pulmonary gas exchange [48-50] that may be of clinical 
signiﬁ   cance [50]. Traumatic injury and compartment 
syndrome may appear to be obvious applications for 
supplementary oxygen – an increased PO2 would help 
overcome the reductions in perfusion – but hyperbaric 
rather than normobaric oxygen is the treatment of choice 
[51-53]. Oxygen is used for the treatment of carbon 
monoxide poisoning [54], but this is probably less 
eﬀ  ective than it should be if the accompanying hypo-
capnia is not prevented [26]. In the case of breathlessness, 
which has long been treated with supplementary oxygen, 
a recent randomized double-blind controlled trial estab-
lished that nasal oxygen was no better than air in reliev-
ing breathlessness and improving quality of life in pallia-
tive care patients with refractory breathlessness [55].
In conclusion, NASA managers demanded in 1986 that 
their counterparts at Martin-Th  iokol prove that it was 
not safe to launch the Space Shuttle Challenger despite 
concerns expressed by engineers about the integrity at 
low temperatures of the O-rings joining the segments of 
the solid rocket boosters [56]. Th  e correct question 
would have been: can you prove that it is safe? In the case 
of supplementary oxygen, failure to ask the right question 
reinforces complacency about its use in patients who may 
have regional hypoxia or ischemia but are not hypoxemic.
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